Search results for Genentech

AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs

Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his days in his backyard, sketching out designs for new antibody-drug conjugates with a friend. Now, he’s sharing with...

<![CDATA[Roche and C4 Therapeutics Expands Partnership with $1 Billion Collaboration Agreement ]]>

Roche to start new Elevidys study following setback in Europe

The Swiss drugmaker, which owns rights to the Duchenne gene therapy outside the U.S., hopes the trial will yield additional approvals in Europe and elsewhere.

Analyst Report: Roche Holding AG

Geron

Geron Anonymous (not verified) Sun, 04/19/2026 - 08:10 field_thread_url https://cafepharma.com/boards/threads/geron.694511/ board name...

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

Roche, MET to open disease treatment hub

Roche boosts diagnostics offerings with $595M Saga buyout

Roche is handing over $595 million to bolster its Foundation Medicine business with a deal to snap up SAGA Diagnostics.

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boos...

Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer

The partnership will automate manufacturing and quality control of ProT-096, ProTgen’s personalized progenitor T-cell therapy for refractory leukemia and other hematologic malignan...

Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.

Proteins.1 Launches to Develop Single Molecule Protein Amplification Tech for Diagnostics

Proteins.1 launches to commercialize a technology enabling ultra-sensitive detection of proteins at the single-molecule level, with the aim of transforming early disease diagnostic...

Foundation Medicine links with Fulgent Genetics to offer new gene test

Roche’s Foundation Medicine has linked with Fulgent Genetics to offer a new diagnostic test that identifies a person’s genetic makeup that can determine how they metabolize and pro...

Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines

Gilead Sciences exercised its option license a Kymera Therapeutics’ protein-degrading drug designed to eliminate the cancer-driving protein CDK2. Meanwhile, Roche’s new partnership...

Regeneron, Telix Launch Up-to-$4.3B Cancer-Focused Radiopharma Drug, Diagnostic Collaboration

The companies have agreed to partner on next-generation radiopharmaceutical therapies aimed at up-to-eight solid tumor targets from Regeneron’s portfolio of antibodies, generated f...

Parabilis Files for IPO, a Day After Signing Up-to-$2.3B Regeneron Collaboration

The company’s IPO filing came a day after Parabilis inked an up-to-$2.3 billion-plus strategic research collaboration with Regeneron Pharmaceuticals to discover and develop an init...

Roche takes 'leap of faith' with $20M bet on C4T’s antibody-targeted protein degraders

Roche has joined Big Pharma peers in the emerging degrader-antibody conjugate space, paying C4 Therapeutics $20 million upfront and committing more than $1 billion in milestones to...

Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development

The collaboration brings together OneCyte's proprietary single-cell platform for high-throughput and high-speed clone selection with Kemp Proteins' molecular engineering capabiliti...

<![CDATA[Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals ]]>

Regeneron, Parabilis Ink Up-to-$2.3B Antibody-Peptide Conjugate Collaboration

Regeneron will marry its antibody capabilities with Parabilis’ stabilized helical peptide or Helicon™ platform, with the goal of developing both Antibody-Helicon™ Conjugates...

Mutating Antibodies for Easier Drug-Conjugate Manufacturing

Mutations engineered into antibodies could help companies developing the next generation of antibody-drug conjugates by providing convenient general-purpose “lock-on” locations for...

<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>